The US Food and Drug Administration today approved a new insulin inhaler for use in treating diabetes, its first in years. The product, which is made by California-based MannKind Corporation, uses a dry powder that people can breath in to control insulin levels. Its been designed not as a full-time replacement to insulin injections, and instead as an alternative to them at meal times given the powders short-term effects that kick in within what the company says is between 12 to 15 minutes. The drug, which goes by the commercial name Afrezza, is the second such insulin inhaler to get FDA approval, and comes after an earlier version of the device was rejected and sent back for additional testing.
Comments are closed.
